A newly-created mouse-human embryo contains up to 4% human cells the most human cells yet of any chimera, or an organism made of two different sets of DNA.
Surprisingly, those human cells could learn from the mouse cells and develop faster at the pace of a mouse embryo rather than a more slowly developing human embryo. That finding was "very serendipitous We did not really foresee that," said senior author Jian Feng, a professor in the department of physiology and biophysics at the State University of New York at Buffalo.
Successfully growing human cells in mouse embryos might one day help scientists understand the growth and aging process of our bodies and how diseases such as COVID-19 damage cells and could eventually even serve as a scaffold to grow organs for transplantation, Feng said.
Related: The 9 most interesting transplants
Feng and his team tackled a long-standing issue in creating such chimeras: that in order for human embryonic stem cells and mouse embryonic stem cells to chat and mingle, they needed to be in the same state of development. Embryonic stem cells are pluripotent, meaning they can develop into any type of cell in the body.
But "the human embryonic stem cell looks and behaves very differently from the mouse embryonic stem cell," so past attempts to get them to comingle have all failed, Feng told Live Science. At first, researchers thought the failures were due to some kind of species barrier; but after many years of study, they realized that it wasn't a species issue, but rather a maturity one.
The human stem cells were in a later stage of development called a "primed" state, which normally occurs only after the human embryo has already been implanted in the uterine wall. In contrast, the mouse stem cells were in a more "naive" state, which normally occurs when the mouse embryo is still floating around in the fallopian tubes. In the past, researchers weren't able to convert human cells back to this naive state, Feng said.
In their experiments, Feng and his team were inspired by a process called "embryonic diapause" that occurs in hundreds of mammals from bears to mice: When there's some sort of hardship such as a famine or shortage of water, some animals' embryos can remain in the naive state inside a mother's fallopian tubes for months and sometimes over a year for the environment to become more suitable, Feng said.
It's not clear what triggers the embryos to pause in this state, but a protein called mTOR seems to be a sensor that detects when conditions are bad, he said. Feng and his team figured out that they could target this protein inside human stem cells to make the cells think that they were experiencing famine, and needed to jump to a more naive state where they could conserve energy, Feng said.
The protein mTOR normally promotes the production of proteins and other molecules to support cell growth and proliferation, so by inhibiting it, Feng and his team "shocked" the human cells into changing their metabolism and gene expression. "So it behaves pretty much like the mouse cell," Feng said. What resulted was a naive set of human stem cells that could be cultured together with mouse stem cells and "intermingle very nicely," Feng said. The researchers then injected 10 to 12 of these naive human stem cells into mouse embryos.
In most of the mouse embryos, the naive human stem cells successfully developed into mature human cells in all three germ layers: the ectoderm, or the primary cell layers that develop when the embryo is growing and which later develop to form hair, nails, the epidermis and nerve tissue; the mesoderm, or the cells that make up the organs; and the endoderm, or the inner lining of organs. But no human cells spilled over into germline tissue, which develops into egg and sperm cells.
These germ layers then developed into more differentiated cells, and when the researchers stopped their experiment on the 17th day, 14 embryos were between 0.1% and 4% human (some had less human cells and some had more), with human cells found through the embryo, including in the liver, heart, retina and red blood cells.
Related: First pig-monkey chimeras were just created in China
But what was really "surprising" was the speed at which the human cells developed, Feng said. For example, the embryos were able to generate human red blood cells in 17 days, compared to the roughly 56 days red blood cells take to develop in a growing human embryo. Similarly, human eye cells don't develop until much later on in the embryo, whereas within 17 days, human eye cells including photo receptors formed in the chimera. Basically, the human cells "assumed the clock of the mouse embryo," Feng said. Previously, scientists thought this accelerated development was impossible because the tempo of human cell development was always thought to be "kind of immutable," he added.
This paper identifies a "novel way" of turning primed human pluripotent stem cells into a naive state, said Ronald Parchem, an assistant professor in the Stem Cells and Regenerative Medicine Center at Baylor College of Medicine in Texas, who was not a part of the study. But "the level of chimerism is low in this study," compared to another study that developed chimeras with up to 20% human cells per embryo, he said. That study, however, was published to the preprint database Biorxiv on May 24,and hasn't yet been peer-reviewed. "Together, these studies provide insight into capturing pluripotent states in vitro and highlight the barriers preventing successful cross-species chimerism," Parchem said. "Identifying ways to overcome these barriers has the potential to improve regenerative medicine."
These findings might "stimulate research" in the fundamental understanding of human development, especially how time is measured by biological systems, Feng said. Such chimeras could help scientists understand human diseases. For example, researchers might one day be able to regenerate human blood in a mouse model and study diseases such as malaria. Or if you can create human lung cells, or epithelial cells that line the respiratory tract, that mouse can become a "model system" for studying diseases like COVID-19, Feng said. In other words, mice with human cells can be infected with COVID-19 to understand how the virus attacks the body.
The most cited potential application of such chimeras is organ growth. But this likely won't happen in mice but much larger animals such as pigs, he said. Of course, these applications raise ethical issues, he added. One such ethical consideration is that chimeras blur the lines between species and that makes it difficult to determine the morality or the consciousness that those animals possess. For example, chimeras used in animal testing could be given too many human characteristics and have a similar moral status or consciousness to us, according to a previous Live Science report.
Feng said that much discussion needs to take place before such applications can be considered.
"This field requires much more exploration before this becomes a reality," said Carol Ware, the associate director at the University of Washington's Institute for Stem Cell and Regenerative Medicine, who was also not a part of the study. "A couple of the primary hurdles at this point are determining the host species for these human cells," and public acceptance in the work, she added.
"At this point, it would seem that the speed with which this clinical opportunity will become a reality will not be hindered by the ability to grow human organs," she added. "I would have liked to see," what happens when mTOR is taken away inside the lab dish and these naive human cells are allowed to advance again, particularly to see if some key cellular processes resume again, she added.
The findings were published in the journal Science Advances on May 13.
Originally published on Live Science.
See more here:
New human-mouse chimera is the most human yet - Livescience.com
- Global Induced Pluripotent Stem Cell ((iPSC) Market to Reach $0 Thousand by 2027 - Yahoo Finance - October 13th, 2022
- Paris-based startup Gourmey uses the Big Idea Ventures accelerator program as a launch pad and goes on to raise the world's largest cultivated meat... - October 13th, 2022
- The New York Stem Cell Foundation Mourns the Loss of CEO Susan L. Solomon - October 4th, 2022
- In Multiple Myeloma, Will ASCT Survive Collision With CAR T-Cell Therapy? - Targeted Oncology - October 4th, 2022
- The global live cell imaging market is expected to grow at a CAGR of 8.44% during 2022-2027 - Benzinga - October 4th, 2022
- Sernova to Participate in the Roth Inaugural Healthcare Opportunities Conference - Sernova (OTC:SEOVF) - Benzinga - October 4th, 2022
- New Study Finds Mouse Embryonic Stem Cells Have No Special - September 25th, 2022
- GMAs Robin Roberts replaced by Cecilia Vega as host is still absent from morning show following emotional... - The US Sun - September 25th, 2022
- Severe COVID-19 caused by senile interferon response in older patients, researchers suggest - EurekAlert - September 25th, 2022
- Money on the Move: Arsenal, ILiAD and a Hefty Gift to UCSD - BioSpace - September 8th, 2022
- How surviving cancer changed this 34-year-olds attitude toward work: The concept of checking email was laughable - CNBC - September 8th, 2022
- Garuda Therapeutics Announces Appointment of Roger Sawhney, M.D., as Chief Financial Officer - Benzinga - September 8th, 2022
- 6 Ingredients to Avoid Putting on Your Skin - Healthline - September 8th, 2022
- Scientists create 'synthetic' embryo with brain, beating heart in 'world first' - New York Post - August 30th, 2022
- Global Cell Banking Outsourcing Market to Grow at a CAGR of ~18% during 2022-2031; Market to Expand Owing to the Development of Advanced Cell... - August 30th, 2022
- Pelvic Reconstruction Market is projected to reach a valuation of US$ 366.9 million by 2032, at a CAGR of 2.8% during 2022-2032 Future Market... - August 30th, 2022
- Global Mesenchymal Stem Cell (MSC) Market to Grow at a CAGR of ~14% during 2022-2031; Market to Grow on the Back of Increasing Prevalence of Chronic... - August 5th, 2022
- Pigs died after heart attacks. Scientists brought their cells back to life. - Popular Science - August 5th, 2022
- Global Hematopoietic Stem Cell Transplant (HSCT) Market to be Driven by Increasing Prevalence of Blood Ca - Benzinga - August 5th, 2022
- Why Are There so Many Books and Shows About Cannibalism? - The New York Times - July 27th, 2022
- Cell Culture Media Market: Competitive Approach, Breakdown And Forecast by 2027 - Digital Journal - July 27th, 2022
- Herminia Pasantes revealed one of taurines big roles in the brain - Science News Magazine - July 27th, 2022
- Shai Efrati, MD, the World's Leading Research Scientist and Innovator in Hyperbaric Medicine, to Keynote at the Global Wellness Summit - PR Web - July 27th, 2022
- Journalist Benita Alexander reveals chilling clue that told her Miracle Man Paolo Macchiarini was a rom... - The US Sun - July 27th, 2022
- Melanoma Kills Nearly Twice The Number Of Men Than Women: Study - Kaiser Health News - July 19th, 2022
- Patients have turned to pricey 'blood washing' to treat long COVID - New York Post - July 19th, 2022
- Affimed Presents Preclinical Data of Novel Innate Cell Engager AFM28 at the Annual Meeting of the European Hematology Association (EHA) -... - July 11th, 2022
- Interferons Market is anticipated to reach US$ 13.8 Bn by 2032, at a CAGR of 3.9% from 2022 to 2032 - Digital Journal - July 11th, 2022
- 'World's Greatest Tuba-Playing Car Salesman' Bounces Back after Leukemia, Thanks to Wilmot Team - URMC - July 3rd, 2022
- Hadjiargyrou Is New York Tech's First Distinguished Professor | Box | New York Tech - New York Institute of Technology - July 3rd, 2022
- The global tissue engineering market is anticipated to reach US$ 13,236.87 million in 2022 and is project - Benzinga - July 3rd, 2022
- He Helped Cure the London Patient of H.I.V. Then He Turned to Covid. - The New York Times - June 13th, 2022
- Biden to Pause New Solar Tariffs as White House Aims to Boost Adoption - The New York Times - June 13th, 2022
- Gamida Cell to Present Corporate Highlights at the Jefferies Healthcare Conference - Business Wire - June 4th, 2022
- ReCode Therapeutics to Present at Jefferies Healthcare Conference - Benzinga - Benzinga - June 4th, 2022
- A Medical History of Transplant Surgery Thats Not for the Squeamish - The New York Times - May 15th, 2022
- Mesenchymal Stem Cells Market to Witness Growth Acceleration | Celprogen Inc., Thermo Fisher Scientific, Inc. Queen Anne and Mangolia News - Queen... - May 15th, 2022
- CORRECTING and REPLACING Paracrine Announces Appointment of Biotech Veteran David H. Crean, Ph.D. to the Board of Directors - Business Wire - May 15th, 2022
- William Blair Begins Coverage on Century Therapeutics (NASDAQ:IPSC) - Defense World - May 15th, 2022
- Aging Brain Initiative awards fund five new ideas to study, fight neurodegeneration - MIT News - May 2nd, 2022
- Treadwell Therapeutics Announces Fast Track Designation Granted by the FDA to CFI-400945 for the Treatment of Acute Myeloid Leukemia - PR Newswire - May 2nd, 2022
- What's Trending in the World of Hair Treatments - NewBeauty Magazine - May 2nd, 2022
- Demand in the US Animal Model Market is set to Increase at a 4.1% CAGR from 2022 to 2032 - Future Market Insights - PR Newswire - May 2nd, 2022
- Actinium Pharmaceuticals, Inc. and Immedica Announce Commercialization Agreement for Iomab-B (131I apamistamab) in Europe, the Middle East and North... - April 19th, 2022
- BioCardia Announces New Center for Medicare and Medicaid Services Reimbursement Code Applicable to the CardiAMP Cell Therapy Procedure - GlobeNewswire - March 25th, 2022
- Hoth Therapeutics Announces it Has Successfully Completed Manufacturing Feasibility of the HT-KIT Drug Substance - Yahoo Finance - March 25th, 2022
- Emendo Biotherapeutics and Seattle Children's Research Institute Announce Collaboration to Develop CRISPR-based Therapeutic Strategy for Severe... - December 24th, 2021
- 2021: The year in review | YaleNews - Yale News - December 24th, 2021
- 15 Truly Unbelievable Ways Science Changed the World in 2021 - Fatherly - December 24th, 2021
- Cargo Dragon Docks to Station with Brand New Science - NASA - December 24th, 2021
- Adaptation Is Key to Advancing Care for Adult Patients With Leukemia - OncLive - December 24th, 2021
- Cytovia Therapeutics' Scientific Leadership to Present at Upcoming Conferences - Business Wire - December 10th, 2021
- A New Stem-Cell Treatment Looks to Have Cured a Man of Type 1 Diabetes - Good News Network - December 10th, 2021
- BrainStorm Cell Therapeutics and Catalent Announce Completion of Technology Transfer for NurOwn Manufacturing - PRNewswire - December 10th, 2021
- Affimed to Host Virtual Investor Call Today to Discuss Treatment of CD30-positive Lymphoma ... - The Bakersfield Californian - December 10th, 2021
- No animals harmed in new chip drug tests that are faster and cheaper - ISRAEL21c - December 10th, 2021
- Stem Cell Therapy for Heart Failure Reduced Major Cardiac Events and Death - Diagnostic and Interventional Cardiology - November 22nd, 2021
- Global Cord Blood Stem Cells Market With An Annual Growth Rate, The Impact Of Covid-19: FAQ The UK Directory - The UK Directory - November 22nd, 2021
- The Beauty Products Violet Greys Cassandra Grey Uses to the Last Drop - The Cut - November 22nd, 2021
- Cellectis to Present Preclinical Data on UCARTMESO Supporting Anti-Tumor Activity at the Society for Immunotherapy of Cancer (SITC) 36th Annual... - October 16th, 2021
- Holy wars against vaccines and science People's World - People's World - October 16th, 2021
- Judge Rules to Uphold Religious Exemption to NY Vax Mandate - wnbf.com - October 16th, 2021
- Investigators Aim to Fill Unmet Need of Intermediate- to High-Risk MDS With ENHANCE Trial - OncLive - October 16th, 2021
- Healthcare Researchers Are Putting HUMAN Immune Systems In Pigs To Study Illnesses-Here's The Tech Behind It - Tech Times - October 5th, 2021
- Losing Your Hair? You Might Blame the Great Stem Cell Escape. - The New York Times - October 5th, 2021
- BrainStorm to Present at the 2021 Cell & Gene Meeting on the Mesa - KKTV 11 News - October 5th, 2021
- Coronavirus: What's happening in Canada and around the world on Tuesday - CBC.ca - October 5th, 2021
- Why Bezos, Musk, Page and other billionaires want to live forever - New York Post - October 5th, 2021
- Court hears dispute over N.Y. healthcare workers seeking COVID vaccine religious exemption - Washington Times - October 5th, 2021
- Glioma subtype may hold the secret to the success of immunotherapies - Michigan Medicine - October 5th, 2021
- Vera Nall: Misinformation will kill us in Southwest Missouri - Joplin Globe - October 5th, 2021
- Meet the Newest Group of Tenured, Tenure-Track Faculty at UT Dallas - University of Texas at Dallas - October 5th, 2021
- Global Stem Cell Banking Market to Reach US$11.3 Billion by the Year 2027 - Yahoo Finance - August 5th, 2021
- COVID-19 Antibody Therapy Now Available For Treatment and Post-Exposure Prophylaxis - PrecisionVaccinations - August 5th, 2021
- Primary Cells Market Research Report by Origin, by Cell Type, by End-user, by Region - Global Forecast to 2026 - Cumulative Impact of COVID-19 - Yahoo... - August 5th, 2021
- BeyondSpring Announces Positive Topline Results from its DUBLIN-3 Registrational Trial of Plinabulin in Combination with Docetaxel for the Treatment... - August 5th, 2021
- 5 days, 11 life science IPOs & more than $1.3B in new capital - MedCity News - August 5th, 2021
- What Its Like To Have Severe Iron Deficiency Anemia - Scary Mommy - August 5th, 2021
- 'Black fungus' infections on the rise in India: report - New York Post - June 23rd, 2021
- Global Cord Stem Cell Banking Market Status, Business Trends, Competitive Analysis, Growth Factors and Forecasts To 2028||Cryo-Cell International,... - June 23rd, 2021